Skip to Content

CHERRY COUGH MIXTURE

View full screen / Print PDF » Download PDF ⇩

PDF Transcript

SUMMARY OF PRODUCT CHARACTERISTICS
1

NAME OF THE MEDICINAL PRODUCT
Cherry Cough Mixture

2

QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 5ml contains:
Squill Liquid Extract BP 0.06ml
Ipecuanha Liquid Extract BP 0.025ml

3

PHARMACEUTICAL FORM
Oral Solution

4

CLINICAL PARTICULARS

4.1

Therapeutic indications
As an aid to expectoration in troublesome coughs associated with colds and catarrh.

4.2

Posology and method of administration
Children aged 2-12 years:
Half a 5ml spoonful to be taken three times a day
Not more than 3 doses should be given in any 24 hours. Do not exceed the
stated dose
Do not take with any other cough and cold medicine.
Consult a pharmacist or other healthcare professional before use in children
under 6 years
For Adults:
One 5ml spoonful to be taken three times a day

4.3

Contraindications
Impaired renal function, impaired hepatic function, cardiac disorders, moderate to
severe respiratory insufficiency, alcoholism and raised intracranial pressure or if
hypersensitive to any of the ingredients.

4.4

Special warnings and precautions for use
The product contains Ipecac and Squill both of which are cardioactive and hence
should not be used in patients receiving anti-arrhythmic therapy. This product
contains sugar. Dental hygiene after each dose is recommended and is best avoided
by diabetic patients. Parabens are used as preservatives and these have been reported
to cause bronchospasm in susceptible individuals. The stated dose should not be
exceeded and if symptoms persist or deteriorate after 5 days treatment doctor should
be consulted.

4.5

Interaction with other medicinal products and other forms of interaction
Theoretical risk of interaction with anti-arrhythmic drugs though this is
unlikely at recommended doses.

4.6

Fertility, pregnancy and lactation
There is no information on or evidence of the safety of squill or Ipecac during
pregnancy or lactation. It should not be used without consulting a physician and then,
only if benefit exceed potential and unknown risks.

4.7

Effects on ability to drive and use machines
None

4.8

Undesirable effects
Gastric irritation, nausea and vomiting. Occasionally moderate to severe diarrhoea
can occur if hypersensitive to squill.

4.9

Overdose
Symptoms of overdose are similar to other undesirable effects stated above but more
exaggerated. When taken in large doses, bloody diarrhoea, mucosal erosion and
albuminuria can occur. If symptoms and signs due to squill dominate, the clinical
picture resembles Digoxin toxicity. Fluid and electrolyte balance together with ECG
should be monitored and other symptomatic and supportive measures should be
provided.

5

PHARMACOLOGICAL PROPERTIES

5.1

Pharmacodynamic properties
The Ipecacuanha extract and Squill extract act as expectorants to relieve sore throats
and thus ease coughing.
The active ingredients have an irritant effect on the mucosa to produce a reflex
expectorant action.

5.2

Pharmacokinetic properties
Squill Liquid Extract contains cardiac glycosides which are absorbed and eliminated
by the kidneys.
Ipecacuanha Liquid Extract contains emetine alkaloids which are absorbed and then
eliminated by the kidneys but they also accumulate in muscles.

5.3

Preclinical safety data
None stated

6

PHARMACEUTICAL PARTICULARS

6.1

List of excipients
Sucrose
Camphor
Aniseed Oil

BP
BP
BP

Benzaldehyde
BP
Amaranth (E123)
BP
Sol of Syrup of Wild Cherry (Conc. 1- BP
7)
Glacial Acetic Acid
BP
Sodium Methylhydroxybenzoate
BP
Sodium Propylhydroxybenzoate
BP
Water
to

6.2

Incompatibilities
None stated.

6.3

Shelf life
3 years

6.4

Special precautions for storage
None.

6.5

Nature and contents of container
Glass bottle with plastic or aluminium cap 100ml

6.6

Special precautions for disposal
None Stated.

7

MARKETING AUTHORISATION HOLDER
Activase Pharmaceuticals Limited,
11 Boumpoulinas, 3rd Floor,
P.C. 1060
Nicosia.
Cyprus

8

MARKETING AUTHORISATION NUMBER(S)
PL 28444/0047

9
DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION
04/01/2012

10

DATE OF REVISION OF THE TEXT
04/01/2012

Expand Transcript

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide